 Vaccitech plc NASDAQ: VACC announced an update to the interim analysis of safety and efficacy data from the HBV002 study evaluating ChAdOx1-HBV and MVA-HBV vaccines VTP-300 in chronic HBV patients who are virally suppressed with oral anti-viral therapies. In the VTP-. 